Quarterly report pursuant to Section 13 or 15(d)

Transactions with BioXcel (Details)

v3.19.2
Transactions with BioXcel (Details)
$ in Thousands
1 Months Ended
Apr. 05, 2018
USD ($)
Nov. 07, 2017
USD ($)
shares
Jul. 31, 2019
USD ($)
Apr. 30, 2019
USD ($)
Jun. 30, 2019
shares
Dec. 31, 2018
shares
Transactions with BioXcel            
Common shares, issued | shares         15,687,546 15,663,221
BioXcel Corporation | Asset contribution agreement            
Transactions with BioXcel            
Common shares, issued | shares   9,480,000        
Lump sum payment to parent   $ 5,000        
Period specified for payment   60 days        
Cumulative net sales   $ 50,000        
Payment to (received from) related party $ (1,000)   $ 500 $ (500)    
Maximum borrowing capacity   $ 1,000        
BioXcel Corporation | Collaborative services agreement            
Transactions with BioXcel            
Term of agreement   5 years        
BioXcel Corporation | Development milestones            
Transactions with BioXcel            
Potential milestone payments   $ 10,000        
BioXcel Corporation | Sales milestones            
Transactions with BioXcel            
Potential milestone payments   $ 30,000        
Maximum milestone (as as percent)   3        
BioXcel Corporation | Payable upon milestones | Asset contribution agreement            
Transactions with BioXcel            
Lump sum payment to parent   $ 1,000        
BioXcel Corporation | Payable upon later 12 months IPO and first dosing for BXCL501 | Asset contribution agreement            
Transactions with BioXcel            
Lump sum payment to parent   $ 500        
Period specified for payment   12 months        
BioXcel Corporation | Payable upon later of 12 months of IPO and specified milestones | Asset contribution agreement            
Transactions with BioXcel            
Lump sum payment to parent   $ 500        
Period specified for payment   12 months